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Abstract
Background: Adiponectin, an adipose-specific protein, is negatively correlated with pro-atherogenic low-density
lipoprotein cholesterol (LDL-C) and other cardiovascular risk factors such as insulin resistance. Therefore, low levels
of adiponectin are associated with a higher risk for diabetes and cardiovascular disease. Dipeptidyl peptidase-4
inhibitors (DPP4i) have been used for the treatment of type 2 diabetes mellitus (T2DM) as reversible inhibitors
through interacting with DPP4 substrate and increase serum incretins such as glucagon-like peptide-1 (GLP-1). The
present study aimed to evaluate the effect of DPP4i on serum adiponectin in T2DM patients.
Methods: The PubMed, Embase, and Cochrane library databases were searched from inception to February 2016.
Randomized controlled trials, evaluating the DPP4i (sitagliptin and vildagliptin) versus comparator (placebo or
active-comparison), in T2DM patients with duration of ≥ 12 weeks, were identified. Weighted differences in means
of adiponectin levels were calculated by using a fixed or random-effects model.
Results: Ten randomized controlled trials, including 1,495 subjects, were identified. Compared with placebo, DPP4i
(sitagliptin and vildagliptin) treatment significantly elevated adiponectin levels by 0.74 μg/mL (95% confidence
interval [CI], 0.45 to 1.03) relative to that using an active-comparison by 0.00 μg/mL (95% CI, −0.57 to 0.56). Compared
with active-comparison, vildagliptin treatment increased adiponectin levels by 0.32 μg/mL (95% CI, −0.01 to 0.65),
whereas sitagliptin treatment decreased adiponectin levels by −0.24 μg/mL (95% CI, −1.07 to 0.58). Trials examining
effects of other DPP4i were not found.
Conclusions: Sitagliptin and vildagliptin increased serum adiponectin levels and had no stronger effect than traditional
oral antidiabetic drugs. Further trials with larger sample size are needed to confirm the results and investigate the
association between serum adiponectin levels and treatment of other DPP-4 inhibitors.
Trial registration: Registration No in PROSPERO: CRD42016037399.
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Background
Obesity is strongly associated with type 2 diabetes melli-
tus (T2DM) and cardiovascular mortality [1]. Therefore,
efforts have been made to better understand mechanisms
underlying the etiology of obesity and cardiovascular dis-
ease. Adipocytes are not only energy-storing cells, but also
secrete bioactive substances such as adiponectin [2, 3].
Adiponectin is an adipose-specific collagen-like protein
that adheres to injured arterial endothelial walls [1]. The
adiponectin gene is located on chromosome 3q27 and has
been linked to metabolic syndrome and T2DM [4].
Adiponectin is often reduced along with insulin resist-
ance progression in T2DM [5].
Previous studies have indicated that adiponectin pos-
sessed favorable anti-diabetic and anti-atherogenic activ-
ities [6, 7]. Adiponectin levels are lower in patients with
T2DM, which is a common co-morbidity of obesity [8].
Adiponectin is positively correlated with insulin sensitiv-
ity in humans and animals [9], and negatively correlated
with myocardial infarctions [10]. Plasma adiponectin levels
are markedly lower in patients with coronary artery dis-
ease compared with age- and BMI-matched controls [11].
Adiponectin also has a cardioprotective effect during
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ischemia-reperfusion injury [12]. Hypoadiponectinemia
has been related to cardiac hypertrophy [13].
Increased adiponectin levels improve atherosclerosis in
patients with T2DM or insulin resistance. Thiazolidine-
diones, which are useful glucose-lowering agents that have
off-target or unwanted side effects, increase adiponectin
levels in humans and mice [14, 15]. GLP-1, mainly in the
form of incretin, increases adiponectin secretion in obese
mice [16]. Dipeptidyl peptidase-4 inhibitors (DPP4i), or
gliptins, lower glucose levels during fasting and post-
prandial states via preventing the inactivation of incretin
hormones [17, 18]. Clinical studies have indicated that
gliptins improve pancreatic β-cell function in T2DM
patients [19, 20]. In animals, administration of DPP4i
increases diet-induced decline in adiponectin levels [21].
Investigations on the effect of gliptin on plasma adiponec-
tin in T2DM patients are limited, and the available data
remains controversial [22–24]. In 2008, the U.S. Food and
Drug Administration and the European Medicines Agency
simultaneously required a demonstration of cardiovascu-
lar safety for all new glucose-lowering medications. Based
on the reported benefits of higher adiponectin levels,
adiponectin may be potentially used as a novel surrogate
cardiovascular indicator and biomarker for antidiabetic
agents. Therefore, to better understand gliptin activity on
adiponectin, a meta-analysis of clinical trial data on DPP4i
was conducted in adult T2DM patients.
Methods
Search strategy
In consultation with a medical librarian, we established a
search strategy for the PubMed, Embase, and Cochrane
Library using the following query terms: “sitagliptin,”
“vildagliptin,” “teneligliptin,” “saxagliptin,” “linagliptin,”
“anagliptin,” or “alogliptin”. Randomized controlled trials
published in English (from inception to February 2016)
were included in the analysis. Two researchers independ-
ently searched for studies and any disagreement was re-
solved through discussion.
Study selection
Studies were included in the meta-analysis when they
described a randomized clinical trial involving T2DM
patients that lasted at least 12 weeks and compared a
drug to a placebo or an active comparator other than a
DPP4i. Exclusion criteria consisted of nonhuman stud-
ies, review articles, observational studies or case reports,
non-glucose-lowering therapies, duplicate publications,
short-term studies (therapies duration of < 12 weeks) and
studies in which changes in adiponectin levels was not
reported or could not be calculated. The corresponding
authors were contacted when clarification on specific
aspects of the study was required. The inclusion and
exclusion criteria were objectively evaluated by two
reviewers.
Data extraction and outcomes
Two researchers (X.L. and P.M.) extracted data and used
a standardized form of recording study information (author,
publication year, sample size, trial duration and controls)
and population characteristics (body mass index, age, sex,
body weight, and baseline levels of glycosylated hemoglobin
and adiponectin). Disagreement was resolved by discussion.
The primary outcome was assessed using the difference be-
tween the final and baseline adiponectin levels. All included
studies recorded mean adiponectin levels compared to that
using placebo or active comparators.
Quality appraisal
Two researchers independently evaluated the quality of
each clinical trial according to the Cochrane risk of bias
tool [25]. This assessment included low, unclear and
high risk for bias based on random sequence generation,
allocation concealment, blinding of participants, blinding
of outcome assessment, incomplete outcome data, select-
ive reporting and other bias. Discrepancies were resolved
by discussion or consultation of a third reviewer.
Statistical analysis
Statistical analysis were performed using Review Manager
(Revman 5.1; Cochrane Collaboration) and STATA 12.0.
Pooled weighted mean differences (WMD) and 95%
confidence intervals (CIs) were calculated using the
Mantel-Haenszel (M-H) fixed effects model when there
was no evidence of significant heterogeneity for outcomes
or a random effects model when significant heterogeneity
for outcomes was present. Heterogeneity among studies
was assessed using a Chi-squared test and quantified using
Higgins I2. To account for low statistical power of the
Chi-squared test for heterogeneity, p = 0.10 was consid-
ered insignificant. I2 ranging from 0 to 50% indicated that
there was no important heterogeneity, and I2 values ran-
ging from 50 to 100% suggested major heterogeneity,
which was further explored using sensitivity analysis.
Publication bias was examined by Egger’s tests if there
were at least five studies for each outcome.
Results
Trial characteristics and quality
Initially, 11,885 citations were found to meet the inclu-
sion criteria. A study inclusion flowchart was presented
in Fig. 1. After removal of inappropriate studies, ten ran-
domized controlled trials including 1,495 subjects were
identified, four studies were performed in Italy, one in
Germany, and five in Japan. Characteristics of the 10
intervention studies are shown in Table 1. Trial quality
was evaluated by using the Cochrane risk of bias tool
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(Fig. 2). Five studies fully fit the seven factors. Two stud-
ies were adequate for six of the seven factors, one study
was adequate for five of the seven factors and two stud-
ies were adequate for four of the seven factors.
Efficacy outcomes
Results of the analysis of gliptin-adiponectin efficacy are
presented in Figs. 3 and 4. Compared with placebo group,
DPP4i (sitagliptin and vildagliptin) treatment significantly
elevated adiponectin levels by 0.74 μg/mL (95% confidence
interval [CI], 0.45 to 1.03; p = 0.74; I2 = 0%; weighted mean
baseline adiponectin: 5.10 ± 0.90 μg/mL vs. 5.30 ± 1.15 μg/
mL) relative to that using an active comparator by 0.00 μg/
mL (95% CI, −0.57 to 0.56; p < 0.01; I2 = 84%; weighted
mean baseline adiponectin: 5.05 ± 2.12 μg/mL vs. 5.10 ±
2.01 μg/mL). Compared to active comparator, vildaglip-
tin increased adiponectin levels by 0.32 μg/mL (95% CI,
−0.01 to 0.65; p = 0.91; I2 = 0%; weighted mean baseline adi-
ponectin: 4.40 ± 2.18 μg/mL vs. 4.41 ± 1.98 μg/mL), whereas
sitagliptin decreased levels by −0.24 μg/mL (95% CI, −1.07
to 0.58; p < 0.01; I2 = 86%; weighted mean baseline adi-
ponectin: 5.71 ± 2.06 μg/mL vs. 5.76 ± 2.03 μg/mL). Tri-
als that examined the effect of other DPP4 inhibitors
were not found.
Heterogeneity and publication bias
A significant heterogeneity was observed in the sitagliptin-
active comparator group and a sensitivity analysis was then
performed in Fig. 5, which indicated that Derosa’s study
had a significant effect on the result. Heterogeneity was
not significant after particular study was excluded from
the analysis (p = 0.48; I2 = 0%), and in turn showed that
sitagliptin had no stronger effect on serum adiponectin
levels compared to traditional oral antidiabetic drugs
(0.26 μg/mL, 95% CI, −0.12 to 0.63; Fig. 6). According
to Egger’s test, no publication bias was observed among
the five sitagliptin studies (p = 0.082).
Fig. 1 Flow chart of studies included in the meta-analysis
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Table 1 Characteristics of the 10 studies included in the meta-analysis




HbA1c (%) Treatment duration
(months)
Patient characteristics
BMI (kg/m2) Age (years) Male (N) Weight (kg)
Derosa, 2012 [22] 91 sitagliptin + metformin 5.8 5.0 8.1 12 28.1 55.9 42 78.4
87 placebo +metformin 5.4 5.2 8.0 28.9 54.8 44 78.6
Derosa, 2010 [23] 75 sitaliptin + pioglitazone 60 5.4 8.5 12 27.9 57 37 78.7
76 metformin + pioglitazone 72 5.3 8.4 27.7 58 39 77.3
Forst, 2013 [45] 22 vildagliptin +metformin 100.8 5.0 7.41 6 Not available Not available Not available 99.3
22 glimepiride +metformin 73.2 5.6 7.28 Not available Not available Not available 93.7
Mikada, 2014 [47] 14 sitagliptin 91.2 6.5 7.45 6 28.8 59.2 11 76.8
14 miglitol 111.6 7.4 6.90 29.5 58.7 11 81.4
Hibuse, 2014 [48] 16 sitagliptin 57.6 6.7 7.5 3 24.9 63 9 Not available
10 sulfonylurea and/or biguanide 45.6 4.6 7.8 28.1 56 6 Not available
Takeshita, 2015 [49] 30 sitagliptin 86.4 4.5 6.7 4 24.5 61.0 18 62.5
30 mitiglinide 145.2 5.0 6.9 24.2 65.8 19 63.2
Derosa, 2012 [50] 84 vildagliptin +metformin 6.1 5.2 8.1 12 27.9 54.2 42 76.9
83 placebo +metformin 6.3 5.4 8.2 27.8 52.4 43 78.5
Derosa, 2014 [51] 86 vildagliptin 6.9 4.8 7.9 6 27.9 59.8 42 77.8
81 glimepiride 6.7 4.5 7.8 27.7 56.8 36 77.2
Takeshita, 2015 [52] 58 vildagliptin Not available 3.6 8.1 3 24.5 Not available 36 63.2
54 liraglutide Not available 3.8 8.0 25.4 Not available 35 65.8
Shimoda, 2014 [53] 25 sitagliptin Not available 7.0 7.3 3 24.9 63.9 16 Not available
















In current meta-analysis, the effect of DPP4i on adipo-
nectin levels in T2DM patients was evaluated based on
10 clinical trials. A pooled efficacy estimate from those
trials indicated that administration of sitagliptin and vil-
dagliptin compared to placebo resulted in an increase in
serum adiponectin levels, yet was not superior to that of
active comparators.
T2DM is positively correlated with morbidity and mor-
tality of diabetic vasculopathies and cardiovascular risks,
including microangiopathies (e.g., renal failure and blind-
ness) and macroangiopathies (atherosclerosis). Cardiovas-
cular disease is a major cause of mortality in T2DM
patients, and insulin or sulphonylureas effectively reduces
the risk for microvascular complications, but not macro-
vascular events [26]. Of note, some studies have indicated
that single and intensive glucose-lowering therapies might
be less favorable to cardiovascular endpoints in T2DM
[27, 28]. Thus, antidiabetic therapy must be performed on
the basis of future cardiovascular aspects.
Body fat distribution, especially visceral fat accumula-
tion, is an early sign of obesity-related disorders such as
cardiovascular disease and is associated with atheroscler-
osis via dysfunctional adipocytes and downregulated
production of protective adipocytokines such as adipo-
nectin. Obesity also decreases adiponectin sensitivity by
downregulating the expression of AdipoR1 and AdipoR2
adiponectin receptors, which in turn leads to insulin re-
sistance [29].
Adiponectin has an insulin-sensitizing effect by activat-
ing adenosine monophosphate activated protein kinase
(AMPK) signaling through binding to AdipoR1 and Adi-
poR2. Then, AMPK stimulates cellular metabolism and
enhances glucose uptake, fatty acid oxidation, and glucose
utilization, thereby causing an increase in insulin sensitiv-
ity [30]. Adiponectin prevents atherosclerosis by inhibiting
the expression of monocyte adhesion molecules and
endothelial synthesis of pro-inflammatory chemokine
by inactivating nuclear factor-kappaB [31, 32] as well as
suppressing proliferation of vascular smooth muscle cells
by targeting extracellular signal-regulated kinase [33].
Adiponectin regulates inflammatory responses in athero-
sclerotic lesions by interacting with IL-10 and upregulating
the expression of tissue inhibitor of metalloproteinase-1
[34]. In apoE-deficient mice, adenovirally-mediated in-
creases in adiponectin levels inhibit the progression of
atherosclerotic lesions by downregulating VCAM-1 and SR-
A [35, 36]. Adiponectin diminishes infarct size, apoptosis
and inflammatory cytokine in ischemia-reperfusion models
through both AMPK- and COX-2-dependent mechanisms
[12]. Adiponectin improves cardiac hypertrophy by inhibit-
ing hypertrophic signaling in the myocardium through the
Fig. 3 Meta-analysis of the effect of DPP4i treatment versus placebo on serum adiponectin levels
Fig. 2 Study quality as evaluated by Cochrane scores
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activation of AMPK and extracellular signal-regulated kinase
(ERK).
PPAR-γ agonists exhibit favorable effects on cardiovas-
cular outcomes in T2DM patients [37, 38]. Thiazolidine-
diones, which are synthetic PPAR-γ ligands, stimulate
serum adiponectin by inducing the expression of the adi-
ponectin gene via direct interaction with the PPAR-γ/
retinoid X receptor (RXR) via peroxisome-proliferator
responsive elements (PPREs) present in the adiponectin
promoter region [39]. Adiponectin-deficient mice do not
show any improvements in atherosclerotic areas after
PPAR-γ activation [40].
Incretin-based therapies, GLP-1 agonists, and DPP4
inhibitors offer optimal glucose-lowering effect without
increasing the risk for hypoglycemia and weight gain [41].
Exendin-4, which is a GLP-1R agonist, upregulates adipo-
nectin mRNA and increases secretion of adiponectin via a
protein kinase A pathway [42]. Inhibition of DPP4 leads to
an increase in the GLP-1 expression, which in turn en-
hances insulin activity. Sitagliptin and vildagliptin resulted
in an increase in adiponectin levels in the current study,
although its underlying mechanism remained unclear.
Due to a significant effect on heterogeneity, Derosa’s study
was excluded according to the sensitivity analysis. One
possible reason for the effect might be the difference of
population race between Derosa’s study (among Italian)
and another four studies (among Japanese). Patient base-
line level of HbA1c in Derosa’s research exceeded 8.0%
while other four studies were between 6.7 to 7.8%, indicat-
ing that baseline levels of glycosylated hemoglobin might
present an effect on adiponectin in response to DPP4i
treatment. Treatment duration might be the third cause of
heterogeneity effect between Derosa’s study (12 months)
and another four studies (3–6 months).
Fig. 5 Sensitivity analysis of the studies reporting the effect of sitagliptin comparing with active control on serum adiponectin levels
Fig. 4 Meta-analysis of the effect of DPP4i treatment versus active comparator on serum adiponectin levels
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Sitagliptin or vildagliptin promotes secretion of adipo-
nectin by enhancing the production of active GLP-1
[43]. Weight reduction or reduced BMI, waist circumfer-
ence, and visceral fat accumulation may also elevate
serum adiponectin levels [8, 44]. Sitagliptin induces a
significant increase in adiponectin levels prior to weight
loss, thereby suggesting that a reduction in visceral fat
mass from long-term treatment causes changes in adipo-
nectin levels [22]. Vildagliptin treatment elevates plasma
adiponectin levels and this may have been due to a re-
duction in fat mass [45]. Speculations might be obtained
that sitagliptin has no better specific selectivity on tar-
geting proteins in the adiponectin-secretion pathway
than active comparators. Oxidative stress can also cause
dysregulation of secretion of fat-derived hormones such
as adiponectin [46]. Sitagliptin or vildagliptin increases
the expression of antioxidative enzymes, as well as pro-
motes adiponectin secretion directly or indirectly by tar-
geting signals of oxidative stress. The role of gliptins in
oxidative stress must be investigated to better under-
stand the mechanism underlying adiponectin secretion.
Limitations
Our study has several limitations such as the inclusion
of a small sample size as well as English-only clinical trials.
Furthermore, unpublished results were not included, which
in turn might cause potential publication bias. Also,
changes in appetite or food intake were not recorded
and the clinical trials were conducted for a short dur-
ation. Some heterogeneity was also observed in some of
the results, although measures were taken to overcome
them by performing a sensitivity analysis. Parallel evalu-
ation of related adipokines was also not performed.
Conclusions
DPP4 inhibitors promote the secretion of serum adipo-
nectin in T2DM patients, thereby indicating that these
have a cardioprotective effect. Further trials with larger
sample size are needed to confirm the results and inves-
tigate the association between serum adiponectin levels
and treatment of other DPP4 inhibitors. Long-term effi-
cacy and cardiovascular endpoints should be studied to
better guide patient treatment with or without other
glucose-lowering agents.
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